Publications Archives

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

2025-11-24T09:51:38-08:00November 24th, 2025|2025 Publications, Featured Publications, Publications|

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib

2025-10-28T11:29:07-07:00September 3rd, 2025|2025 Publications, Featured Publications, Publications|

A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML

2025-07-29T15:39:42-07:00July 29th, 2025|2025 Publications, Featured Publications, Publications|

Performance Comparison of Illumina^® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack^® Assays

2025-09-18T16:16:23-07:00May 27th, 2025|2025 Publications, Featured Publications, Publications|

From prognostication to precision in acute myeloid leukemia

2025-05-08T16:47:49-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

2025-05-09T09:20:30-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina^® MiSeq^TM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

2026-01-07T13:13:14-08:00November 8th, 2024|2024 Publications, Featured Publications, Publications|

Performance Comparison of Invivoscribe’s LymphoTrack^® Assays Between Complete Genomics DNBSEQ-G99 and Illumina^® MiSeq^TM NGS Platforms

2025-09-18T16:19:52-07:00November 8th, 2024|2024 Publications, Featured Publications, Publications|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

2025-09-18T16:20:55-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

Leveraging Standardized MRD Assays to Guide CLL Treatment

2024-01-25T10:44:11-08:00January 25th, 2024|2024 Publications, Featured Publications, Publications|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

2023-04-10T20:22:16-07:00March 23rd, 2023|2023 Publications, Featured Publications, Publications|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

2024-08-02T14:22:45-07:00March 7th, 2023|2023 Publications, Featured Publications, Publications|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

2023-04-10T20:24:04-07:00March 2nd, 2023|2023 Publications, Featured Publications, Publications|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

2022-12-29T21:22:21-08:00November 15th, 2022|2022 Publications, Featured Publications, Publications|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

2022-12-29T21:19:31-08:00June 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

2023-01-08T18:20:36-08:00May 30th, 2022|2022 Publications, Featured Publications, Publications|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

2022-09-07T22:22:23-07:00May 3rd, 2022|2022 Publications, Featured Publications, Publications|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

2022-01-06T05:38:03-08:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

2022-01-08T23:37:03-08:00December 28th, 2021|2021 Publications, Publications|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

2022-01-04T04:43:02-08:00December 8th, 2021|2021 Publications, Publications|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

2022-01-30T21:35:17-08:00November 5th, 2021|2021 Publications, Publications|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.